A meta‐analysis of six publications showed that positive PD‐L1 expression was not associated with OS or PFS in patients with advanced NSCLC harboring EGFR mutations that received EGFR–TKIs [25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.